IP Library Granted Patent US 10,632,047
Granted Patent B2
US 10,632,047 · App. 15/684,430 · Granted Apr 28, 2020

Methods, compositions, and devices for supplying dietary fatty acid needs

Inventors: Alexey L. Margolin (Newton, MA); Robert Gallotto (Newton, MA); Bhami Shenoy (South Grafton, MA)
Assignee: Alcresta Therapeutics, Inc.
A61J15/0092A23D7/011A23D7/013A23D9/013A23K20/158A23K50/30A23L29/06A23L33/115A23L33/12A23L33/40A61J15/0003A61J15/0026A61K9/0029A61K31/202A61K38/465B65D1/02B65D41/02B65D81/32B65D85/72C12Y301/00A23V2002/00C12Y301/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,632,047
App. No.
15/684,430
Granted
Apr 28, 2020
Kind
B2
Abstract

Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.

Claims (32)

1. An enteral feeding device comprising:

a container for receiving a nutritional composition;

at least one opening in the container, wherein the at least one opening is configured for connecting the enteral feeding device to a feeding tube; and

a lipase immobilized within the container so that the nutritional composition is exposed to the lipase when the nutritional composition is received within the container,

wherein the lipase is configured to hydrolyze polyunsaturated fatty acid (PUFA) triglycerides and/or PUFA esters within the nutritional composition to form a nutritional formula.

2. The device of claim 1 , wherein the lipase is immobilized such that when the nutritional formula exits the container, the lipase remains in the container.

3. The device of claim 1 , wherein the lipase is immobilized to an inner surface of the container.

4. The device of claim 1 , wherein the lipase is immobilized to a structure within the container.

5. The device of claim 4 , wherein the structure comprises balls or beads within the container.

6. The device of claim 1 , wherein the at least one opening includes a connector for connecting to the feeding tube.

7. The device of claim 1 , wherein the feeding tube is a nasogastric tube or a nasojejunal tube.

8. The device of claim 1 , wherein the lipase is immobilized by one or more of adsorption, ionic binding, covalent binding, cross-linking, encapsulation, or entrapment.

9. The device of claim 1 , wherein the lipase is selected from a group consisting of Chromobacterium viscosum lipase, Pseudomonas fluorescens lipase, and Rhizopus oryzae lipase.

10. The device of claim 1 , wherein the container includes a syringe barrel.

11. A device comprising:

a container for receiving a nutritional composition;

at least one opening in the container, wherein the at least one opening is connected to a feeding tube;

a plurality of balls or beads contained within the container; and

a lipase immobilized to the balls or beads so that the nutritional composition is exposed to the lipase when the nutritional composition is received within the container,

wherein the lipase is configured to hydrolyze polyunsaturated fatty acid (PUFA) triglycerides and/or PUFA esters within the nutritional composition to form a nutritional formula.

12. The device of claim 11 , wherein the container is a syringe barrel.

13. The device of claim 11 , wherein the feeding tube is a nasogastric tube or a nasojejunal tube.

14. The device of claim 11 , wherein the balls or beads remain within the container when the nutritional formula exits the container.

15. The device of claim 11 , wherein the lipase is immobilized such that when the nutritional formula exits the container, the lipase remains in the container.

16. An enteral feeding device, comprising:

a container for receiving a nutritional composition;

at least one opening in the container, wherein the at least one opening is configured for connecting the enteral feeding device to a feeding tube; and

a lipase immobilized within the container so that the nutritional composition is exposed to the lipase when the nutritional composition is received within the container,

wherein the lipase is configured to hydrolyze polyunsaturated fatty acid (PUFA) triglycerides and/or PUFA esters within the nutritional composition to form a nutritional formula,

wherein immobilization of the lipase limits the amount of lipase that enters into the nutritional composition when the nutritional composition is exposed to the lipase.

17. The device of claim 16 , wherein the feeding tube is a nasogastric tube or a nasojejunal tube.

18. The device of claim 16 , wherein the at least one opening includes a connector for connecting to the feeding tube.

Assignments (5)
SECURITY INTEREST Recorded Mar 12, 2024
From: ALCRESTA THERAPEUTICS, INC.
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 066742/0319 →
TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT (PATENTS) AT REEL/FRAME: 058415/0114 Recorded Mar 12, 2024
From: SILICON VALLEY BANK, A DIVISION OF FIRST-CITIZENS BANK & TRUST COMPANY
To: ALCRESTA THERAPEUTICS, INC.
Reel/Frame 066799/0356 →
SECURITY INTEREST Recorded Dec 17, 2021
From: ALCRESTA THERAPEUTICS, INC.
To: SILICON VALLEY BANK
Reel/Frame 058415/0114 →
CHANGE OF NAME Recorded Sep 25, 2017
From: ALCRESTA, INC.
To: ALCRESTA THERAPEUTICS, INC.
Reel/Frame 043990/0985 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2017
From: GALLOTTO, ROBERT; SHENOY, BHAMI; MARGOLIN, ALEXEY
To: ALCRESTA, INC.
Reel/Frame 043663/0787 →
Continuity (6)
Continuation 15587513 · May 5, 2017
Continuation 15240596 · Aug 18, 2016
Continuation 14378856
Provisional Application 61719173 · Oct 26, 2012
Provisional Application 61600207 · Feb 17, 2012
Related Publication 20170348198A1 · Dec 7, 2017